by
The Organ Transplant Immunosuppressant Drugs Market consists of drugs that are used to suppress the immune system and prevent rejection of transplanted organs such as kidneys, heart, lungs, and liver. Immunosuppressant drugs help modulate the immune system’s response against foreign tissues and reduce the probability of organ rejection. The development of new immunosuppressant drugs with improved efficacy and safety profiles is driving their adoption.
The Global Organ Transplant Immunosuppressant Drugs Market is estimated to be valued at US$ 5.96 Bn in 2024 and is expected to exhibit a CAGR of 46% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the Organ Transplant Immunosuppressant Drugs Market are ABB, Universal Robots, FANUC Corporation, Techman Robot, AUBO Robotics, KUKA, Kawada Robotics, Productive Robotics, Kawasaki Robotics, Precise Automation, Yaskawa, F&P Robotics, Rethink Robotics, Robert Bosch, MABI Robotic, Siasun, Franka Emika, Hanwha Precision Machinery, Carbon Robotics, Han€TMs Robot, ST Robotics, and Others. The increasing prevalence of chronic diseases necessitating organ transplantation is a major factor fueling the demand for immunosuppressant drugs. The growing aging population and higher susceptibility to diseases in the later stages of life is contributing to the rising transplant procedures worldwide.
North America dominated the Global Organ Transplant Immunosuppressant Drugs Market Size in 2020 owing to the rising prevalence of chronic kidney diseases, increasing healthcare expenditure, growing awareness about transplantation, and well-established healthcare infrastructure. However, Asia Pacific is expected to witness the fastest growth during the forecast period owing to the rising number of organ transplantation procedures, increasing focus of key players on emerging markets, and improving healthcare infrastructure.
Market key trends
The rising preference for combination therapies to minimize toxic side effects of high-dose immunosuppressant drugs is a key trend gaining traction in the market. Combination therapies using two or more drugs with different mechanisms of action help achieve the desired therapeutic effects at lower doses, resulting in reduced toxicity. This trend is expected to positively influence the volumes of immunosuppressant drugs consumed during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate due to high capital requirement and established distribution channels of existing players.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of substitute drugs.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitutes.
Threat of new substitutes: The threat of new substitutes is moderate due to stringent regulatory requirements for approval of new drugs.
Competitive rivalry: The competitive rivalry is high due to presence of established global players.
Geographical Regions
North America currently dominates the organ transplant immunosuppressant drugs market in terms of value owing to high prevalence of organ transplantation procedures. According to the U.S. Department of Health and Human Services, around 114,000 transplants were performed in the U.S. from January to December 2020 alone.
Asia Pacific is expected to be the fastest growing region for the organ transplant immunosuppressant drugs market during the forecast period. This is attributed to growing population, increasing healthcare expenditure, rising incidence of chronic diseases, and increasing initiatives by public-private organizations to promote organ donation in countries such as China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
